NasdaqCM - Nasdaq Real Time Price USD

OncoCyte Corporation (OCX)

2.5600

-0.0300

(-1.16%)

At close: April 18 at 4:00 PM EDT

2.3300

-0.23

(-8.98%)

Pre-Market: 5:46 AM EDT

Oncocyte Reports Full Year 2023 Financial Results

Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP$15.8 million in gross proceeds received from private placement offering$4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, res

GlobeNewswire 7 days ago

OCX
-1.16%
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per

GlobeNewswire 7 days ago

OCX
-1.16%
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c

GlobeNewswire 7 days ago

OCX
-1.16%
BIO

BIO-B
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to di

GlobeNewswire 9 days ago

OCX
-1.16%
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico

GlobeNewswire 3 months ago

OCX
-1.16%
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi

GlobeNewswire 4 months ago

OCX
-1.16%
OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon

Strategic Focus on Upcoming Product Launches Amidst Tightened Cash Burn Management

GuruFocus.com 5 months ago

OCX
-1.16%
Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re

GlobeNewswire 5 months ago

OCX
-1.16%
Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issu

GlobeNewswire 5 months ago

OCX
-1.16%
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.

ACCESSWIRE 6 months ago

OCX
-1.16%
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C.

ACCESSWIRE 7 months ago

OCX
-1.16%
Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company's VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).

ACCESSWIRE 7 months ago

OCX
-1.16%
Oncocyte Reports Second Quarter 2023 Financial Results

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023.

ACCESSWIRE 8 months ago

OCX
-1.16%
Oncocyte Regains Compliance With Nasdaq Listing Requirements

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

ACCESSWIRE 8 months ago

OCX
-1.16%
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023.

ACCESSWIRE 8 months ago

OCX
-1.16%
Oncocyte To Announce Second Quarter 2023 Financial Results

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m.

ACCESSWIRE 8 months ago

OCX
-1.16%
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced the publication of new data demonstrating VitaGraft Kidney’s novel ability to help physicians treat kidney transplant patients more precisely, quickly, and effectively. The te

GlobeNewswire 8 months ago

OCX
-1.16%
Oncocyte Announces 1-For-20 Reverse Stock Split

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the Company’s common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the Company’s existing trading symbol

GlobeNewswire 8 months ago

OCX
-1.16%
Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. A method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early acces

GlobeNewswire 9 months ago

OCX
-1.16%
Oncocyte Corporation to Present at the LD Micro Invitational XIII

Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.Oncocyte Corporation is scheduled to present on June 6th at 10:00 AM PT. Josh Riggs, President & CEO, will be ...

Newsfile 10 months ago

OCX
-1.16%

Performance Overview

Return	OCX	S&P 500
YTD	+2.40%	+5.06%
1-Year	-58.44%	+20.71%
3-Year	-97.33%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OncoCyte Corporation (OCX)

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon

Oncocyte Reports Third Quarter 2023 Financial Results

Oncocyte to Announce Third Quarter 2023 Financial Results

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Reports Second Quarter 2023 Financial Results

Oncocyte Regains Compliance With Nasdaq Listing Requirements

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Oncocyte To Announce Second Quarter 2023 Financial Results

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Performance Overview